The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HBIO | -83.4% | -87.15% | -33.65% | -95% |
| S&P | +14.5% | +93.32% | +14.09% | +399% |
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.
The company reported improved revenue in Q1.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $20.45M | -11.5% |
| Gross Profit | $10.37M | -12.8% |
| Gross Margin | 50.71% | -0.8% |
| Market Cap | $19.62M | -84.1% |
| Market Cap / Employee | $0.06M | 0.0% |
| Employees | 355 | -14.7% |
| Net Income | -$2.28M | 22.0% |
| EBITDA | $1.00M | 1708.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.44M | 83.8% |
| Accounts Receivable | $11.94M | -4.4% |
| Inventory | 22.3 | -11.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $7.00M | -80.9% |
| Short Term Debt | $36.32M | 660.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -54.93% | -47.1% |
| Return On Invested Capital | -7.01% | -2.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $2.36M | 241.9% |
| Operating Free Cash Flow | $2.45M | 389.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.80 | 1.41 | 0.39 | 1.32 | -26.45% |
| Price to Sales | 1.20 | 1.00 | 0.27 | 0.22 | -81.92% |
| Price to Tangible Book Value | -26.32 | -20.64 | -6.06 | -4.61 | -90.44% |
| Price to Free Cash Flow TTM | 18.47 | 138.84 | 65.34 | 4.46 | -72.34% |
| Enterprise Value to EBITDA | 2084.78 | 69.03 | 405.19 | 55.70 | -102.14% |
| Free Cash Flow Yield | 5.4% | 0.7% | 1.5% | 22.4% | 261.59% |
| Return on Equity | -20.4% | -18.2% | -138.8% | -138.4% | 824.10% |
| Total Debt | $45.69M | $44.50M | $44.61M | $43.31M | 4.49% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
